drugset / Trial / NCT04632069

NAC +taVNS in IDM Who Are Poor Oral Feeders

NCT04632069

NaSingle-groupOpen-labelTreatment

Summary

Infants of diabetic mothers who are failing to learn oral feeding by term age equivalence have greater CNS oxidative stress, which interact to predict poor neuroplasticity response to transcutaneous vagus nerve stimulation paired with oral feeding. We propose treating the oxidative stress in IDM infants prior to initiating taVNS, with an FDA-approved antioxidant (N-acetylcysteine, NAC) to improve CNS oxidative stress, which in turn regulates expression of many genes including BDNF, that may enhance motor learning.

Timeline

Start
2021-08-12
Primary completion
2024-03-01
Completion
2024-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 75 mg/kg Other